MarketResearchReports.Biz has announced addition of new report “Global Systemic Psoriasis Therapeutics Market 2016-2020” to its database.
About the Systemic Psoriasis Therapeutics Market
Psoriasis is a commonly diagnosed immune-mediated disease of the skin. In psoriasis, the skin grows fast and causes a build-up of red, thick white, or silvery patches. It modifies the normal cell cycle of the skin such that new cells move to the surface of the skin quickly to form patches called plaques. These plaques are commonly found on the knees, elbows, scalp, hand and feet. The condition mostly occurs among adults (18 years-35 years), but can also be seen in adolescents (12 years-18 years) and children (under 10 years).
Psoriasis is more prevalent among Caucasians compared to African-Americans. According to a World Health Organization (WHO) document of 2015, the global prevalence of psoriasis is approximately 2%-3%. However, it is approximately 4.6% in developed countries. In addition, the risk of an individual getting diagnosed with psoriasis is 41% if both parents have psoriasis, 14% in case one parent is affected, and 6% if a sibling has psoriasis.
Technavios analysts forecast the global systemic psoriasis therapeutics market to grow at a CAGR of 9.41% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global systemic psoriasis therapeutics market for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the from the sales of branded, generic, and off-label drugs used to treat psoriasis. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio’s report, Global Systemic Psoriasis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
AbbVie
Johnson & Johnson
Celgene
Amgen
Pfizer
Download Sample Copy of Report at http://www.marketresearchreports.biz/sample/sample/756228
Other prominent vendors
AbGenomics
Almirall
Anacor Pharmaceuticals
ApoPharma
Astellas Pharma
AstraZeneca
Aurinia Pharmaceuticals
Biocon
Biogen Idec
Biotest
Boehringer Ingelheim
Bristol-Myers Squibb
Can-Fite BioPharma
Cellceutix Corporation
Coherus Biosciences
Creabilis
Crescendo Biologics
Delenex Therapeutics
Dermira
Eli Lilly
- Hoffmann-La Roche
Forward Pharma
G & W Laboratories
GlaxoSmithKline
Idera Pharmaceuticals
Incyte
Kadmon
kinetabio
KPI Therapeutics
Kyowa Hakko Kirin
LEO Pharma
Maruho
Merck
Mitsubishi Tanabe Pharma
Moleculin
MorphoSys
Novartis
Prism Pharma
Promius Pharma
Prothena Biosciences
Provectus Biopharmaceuticals
Sandoz
Sun Pharmaceuticals
Takeda Pharmaceuticals
Taro Pharmaceuticals
TFS
UCB
Valeant Pharmaceuticals
VBL Therapeutics
XenoPort
Ziarco Pharma
Market driver
Dominance of market by biologics
For a full, detailed list, view our report
Market challenge
Physician’s reluctance to prescribe biosimilars
For a full, detailed list, view our report
Market trend
Advent of biologics with novel MOA and cell-based strategies
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?